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Abstract 
Purpose  
Based on a clinical observation, this study was initiated to examine whether treatment 
with lamotrigine (LTG) is associated with an increased risk of sudden unexpected 
death in epilepsy (SUDEP) in sub-groups of epilepsy patients, and to explore the 
underlying causes of the increased mortality rate in the epilepsy population. 
Materials and methods 
A nested case-control study of SUDEP in Rogaland county, Norway was conducted by 
review of post mortem reports, data from the Norwegian Cause of Death Registry, and 
hospital records. We also examined twenty-six newly diagnosed epilepsy patients by 
signal-averaged and standard electrocardiography. Fifteen patients were treated with 
LTG and ten with carbamazepine (CBZ). Furthermore the causes of death (COD) of 
deceased epilepsy patients at Stavanger University Hospital were compared with the 
COD in the general population. 
Results 
The incidence of SUDEP was significantly elevated in females on LTG, and a 
significantly higher proportion of female SUDEP victims were on LTG compared with 
controls. 
No significant electrocardiographic abnormalities were detected in the 25 patients that 
completed the study. 
A significantly lower proportion of deceased epilepsy patients had died from cardiac 
disease compared with the general population. In a significant proportion of cases, the 
onset of the disorder leading to death had preceded the onset of epilepsy.                                             
Conclusions                                                                                                                
Treatment with LTG in females was significantly associated with SUDEP. However, it 
remains uncertain whether a causal relationship is present. We found no evidence of 
cardiac abnormalities caused by LTG or CBZ. Comorbid and underlying disorders 
were the main determinants of mortality in the epilepsy population.                                                      
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Introduction 
Since ancient times people have tried to understand epilepsy. The first known 
description of epileptic seizures derives from Babylonian tablets from more than 500 
years BC (Wilson & Reynolds 1990). Seizures were claimed to be caused by ghosts 
and demons, and the sufferers were “possessed”. Although scientists gradually 
abandoned these perceptions through the centuries, they are still present in the 
community to some extent, and not only in developing countries (Chaudhary et al. 
2011). Even in modern society, there is considerable stigma associated with epilepsy, 
adding to the burden of living with this condition (McNeil et al. 2012).      
 
1.1 Definition of epileptic seizure and epilepsy 
According to the 2005 proposal from the International League Against Epilepsy 
(ILAE) and the International Bureau for Epilepsy (IBE) (Fisher et al. 2005) an 
epileptic seizure is a “transient occurrence of signs and/or symptoms due to abnormal 
excessive or synchronous neuronal activity in the brain”, and epilepsy is a “disorder 
of the brain characterized by an enduring predisposition to generate epileptic seizures 
and by the neurobiologic, cognitive, psychological, and social consequences of this 
condition. The definition of epilepsy requires the occurrence of at least one epileptic 
seizure.” 
The possibility of diagnosing epilepsy after a single seizure contrasts with the previous 
definition that required recurrent epileptic seizures (Blume et al. 2001). 
1.2 Incidence and prevalence 
Epilepsy is one of the most common chronic neurological disorders (MacDonald et al. 
2000) and it has been estimated that 50 million people globally have epilepsy 
(Brundtland 2001; Leonardi & Ustun 2002; Birbeck 2012). In developed countries the 
incidence in the general population is about 30 - 50/100.000 per year (Zarrelli et al. 
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1999; MacDonald et al. 2000; Kotsopoulos et al. 2002; Sander 2003; Olafsson et al. 
2005) and the prevalence is about 7 per 1000 (Hauser et al. 1991; Sander 2003; French 
& Pedley 2008). In developing countries the reported prevalence is higher; up to 10 
per 1000 (Placencia et al. 1992; Aziz et al. 1994; Sander 2003) . According to a meta-
analysis of forty incidence studies, the median annual incidence of epilepsy in 
developing countries is 68.7 per 100.000, compared with 43.4 per 100.000 in 
developed countries (Kotsopoulos et al. 2002). Although onset of epilepsy may occur 
at any age, it is more common in children and young people and in the elderly (figure 
1) (Olafsson et al. 2005). 
Figure 1 Age-related incidence of epilepsy and unprovoked seizures  
 
From Olafsson et al.(Olafsson et al. 2005) 
1.3 Classification of epileptic seizures, epilepsies and epileptic syndromes 
The 1981 and 1989 proposals from the ILAE for classification of epileptic seizures 
(ILAE, 1981), epilepsies and epileptic syndromes (ILAE, 1989) have, to date, been 
widely used in the scientific literature. A revised terminology and classification system 
for seizures and epilepsies have recently been proposed by the ILAE (Berg et al. 
2010). However, this new proposal has been debated (Panayiotopoulos 2011; Luders 
et al. 2012; Panayiotopoulos 2012) and is not currently approved by the ILAE and will 
therefore not be further reviewed here.     
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Epileptic seizures (ILAE, 1981) are classified according to ictal semiology and 
electroencephalographic findings as partial, generalized or unclassified. Partial 
seizures originate in a part of one cerebral hemisphere, whereas generalized seizures 
have an initial bilateral hemispheric involvement. In simple partial seizures (SPSs) the 
consciousness is not impaired and the patient has motor, somatosensory or special-
sensory, autonomous or psychic symptoms or signs. Complex partial seizures (CPSs) 
are characterized by impaired consciousness and may be accompanied by similar 
symptoms as SPSs and sometimes also automatisms. Seizures may start as SPS and 
evolve to CPS, or they may start directly as CPS. Both seizure types can evolve to a 
secondary generalized tonic-clonic seizure (GTCS). Generalized seizures include 
myoclonic, clonic, tonic, tonic-clonic and atonic seizures, and also absences and 
atypical absences that are characterized by impaired consciousness, sometimes with 
mild motor signs. 
The epilepsies and epileptic syndromes (ILAE, 1989) are categorized as localization-
related, generalized, undetermined (whether generalized or localization-related) or 
“special syndromes”, which include provoked seizures. The localization-related and 
generalized epilepsies and epilepsy syndromes are further classified as symptomatic, 
cryptogenic or idiopathic, depending on aetiology. In symptomatic cases there is an 
identified acquired cause (e.g. a brain tumour or traumatic brain injury), whereas in the 
idiopathic epilepsies the aetiology is presumed to be genetic. In cryptogenic epilepsy 
the cause of epilepsy is unknown, but presumed to be symptomatic.     
1.4 Aetiology of epilepsy 
A number of diseases or abnormalities affecting the brain have been associated with 
epilepsy (Hauser et al. 1996; Bhalla et al. 2011; Shorvon 2011b). The aetiologies may 
be divided into genetic, developmental (e.g. malformations of cortical development), 
metabolic, neoplastic, cerebrovascular, infectious, inflammatory, traumatic and 
degenerative (Bhalla et al. 2011). In only a small number of cases a purely genetic 
cause may be identified (Heron et al. 2007; Shorvon 2011a). Likewise, only a very 
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small proportion of cases are considered to be purely symptomatic or “environmental”, 
resulting from a known cause and without a genetic component of causality. The 
majority of epilepsies, however, result from a complex interplay between genes and 
environment with varying degrees of genetic influence (figure 2) (Heron et al. 2007).   
Figure 2 The relationship between genetic and environmental aetiologies in epilepsy.  
 
ADNFLE, autosomal dominant nocturnal frontal lobe epilepsy; GEFS+, generalized epilepsy with febrile 
seizures plus; IGE, idiopathic generalized epilepsy. From Heron et al. (Heron et al. 2007)  
In a population-based study from Rochester, Minnesota, USA a cause of epilepsy was 
identified in 25 % of prevalent (Hauser et al. 1996) and 32 % of incident cases 
(Annegers et al. 1996). Similarly, in a later community-based study from Iceland, the 
aetiology was identified in 33 % of all incident cases of unprovoked seizures and 
epilepsy (Olafsson et al. 2005). The proportion of cases with an identified cause was 
lowest in patients younger than 15 years (13 % - 18/134), and highest in those over 64 
years of age (59 % - 66/112). In the youngest age group the most common cause was 
cerebral palsy (5 % - 7/134), whereas among the elderly over 64 years the leading 
causes were degenerative brain disease (25 % - 28/112) and stroke (23 % - 26/112). 
Among the 501 cases in the cohort of incident unprovoked seizures and epilepsy, 53.3 
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% were cryptogenic, 32.1 % symptomatic and 14.6 % idiopathic (71/501 cases) or 
genetic (2/501).   
1.5 Aspects of pathophysiology 
Ion channels are macromolecules that are integrated in the membranes of all living 
cells (Sigworth 2003). By allowing, under certain conditions, ions to pass through their 
specific channel in the lipid membrane, they are fundamental for the cell’s energy 
production and osmotic stabilization (Hille et al. 1999) and also for the normal 
function of the excitable tissues of the nervous system and muscles (Moody & Bosma 
2005; Kullmann 2010). They are “involved in every thought, every perception, every 
movement, every heartbeat” (Hille et al. 1999). 
Mutations in genes coding for ion channels or their interacting proteins have been 
detected in many inherited neurological and skeletal muscle disorders and also in 
cardiac disease (Hedley et al. 2009; Ryan & Ptacek 2010). The mutations cause 
abnormal channel function, and the associated disorders are termed channelopathies. 
Many of these share the common feature that the patients experience episodes of 
impaired function that may be provoked by environmental factors like physical or 
emotional stress (Hanna 2006; Hedley et al. 2009; Ryan & Ptacek 2010). Although  
most of the mutations that have been detected to date are dominantly inherited, the 
phenotypes of family members with a particular single gene mutation may differ 
widely. This phenotypic heterogeneity may reflect variable penetrance, the influence 
of other genes, or environmental factors (Kullmann 2010). In addition, 
channelopathies may be genotypically heterogeneous, i.e. mutations in different single 
genes may give rise to the same phenotype (Hirose 2006).  
 
1.5.1 Channelopathies in epilepsy 
 
During the past two decades an increasing number of mutations in single genes coding 
for sodium-, potassium-, calcium- and chloride channels, and also the nicotinergic 
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acetylcholine and the gamma amino butyric acid (GABA) receptors, have been 
detected in different epilepsy syndromes. Among these, mutations in genes coding for 
different subunits of the sodium channel are the most common (Oliva et al. 2012). 
Mutations in the neuronal sodium channel gene SCN1A have been found to cause 
severe myoclonic epilepsy of infancy (SMEI) (Dravet syndrome) (Claes et al. 2001) 
and generalized epilepsy with febrile seizures plus (GEFS+) (Escayg et al. 2000b), 
mutations in the SCN1B gene have been associated with GEFS+ (Wallace et al. 1998), 
and SCN2A mutations have been associated with benign familial neonatal-infantile 
seizures (BFNIS) (Berkovic et al. 2004). Familial GEFS+ includes a range of 
phenotypes, from febrile seizures only to epilepsies with generalized or sometimes 
focal seizures (Mahoney et al. 2009; Scheffer 2011). Mutations in the neuronal 
potassium channel genes KCNQ2 (Biervert et al. 1998; Singh et al. 1998) and KCNQ3 
(Charlier et al. 1998) have been shown to cause benign familial neonatal convulsions 
(BFNC), whereas a mutation in another gene (KCNA1) coding for the potassium 
channel Kv1.1 has been associated with partial epilepsy (Zuberi et al. 1999), and a 
mutation in a calcium-sensitive potassium channel (BK) gene with generalized 
epilepsy (Du et al. 2005). Mutations in the calcium channel genes CACNB4 (Escayg et 
al. 2000a) and CACNA1H (Chen et al. 2003) have been detected in idiopathic 
generalized epilepsy (IGE) and childhood absence epilepsy (CAE), respectively, while 
mutations in the chloride channel gene CLCN2 have been associated with IGE (Saint-
Martin et al. 2009). Furthermore, mutations in genes coding for different subunits of 
the inhibitory ligand-gated GABAA receptor have been detected in autosomal 
dominant juvenile myoclonic epilepsy (JME) (Cossette et al. 2002), GEFS+ (Baulac et 
al. 2001), childhood absence epilepsy and febrile seizures (Wallace et al. 2001; 
Maljevic et al. 2006; Tanaka et al. 2008), and mutations in nicotinergic acetylcholine 
receptor genes have been shown to cause autosomal dominant nocturnal frontal lobe 
epilepsy (Steinlein et al. 1995; De Fusco et al. 2000). 
IGE encompasses eight different epilepsy syndromes: GEFS+, benign myoclonic 
epilepsy of infancy, CAE, juvenile absence epilepsy (JAE), JME, epilepsy with 
myoclonic-astatic seizures, epilepsy with myoclonic absences and epilepsy with tonic-
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clonic seizures only (Nordli 2005). The syndromes show considerable genetic 
heterogeneity and, although many different single gene mutations causing autosomal 
dominant epilepsy have been detected, cases of IGE are commonly considered to have 
a polygenic origin that might also be influenced by environmental factors (Heron et al. 
2007).  
 
Interestingly, mutations in ion channel genes may be associated with both epilepsy and 
other neurological diseases. For instance, mutations in the potassium channel gene 
KCNA1 have been detected in both episodic ataxia and epilepsy (Zuberi et al. 1999), 
mutations in the potassium channel gene KCNMA1 in paroxysmal movement disorder 
and epilepsy (Du et al. 2005), and mutations in the sodium channel gene SCN1A in 
familial hemiplegic migraine and epilepsy (Dichgans et al. 2005).  
 
1.5.2 Cardiac channelopathies 
The long QT syndrome (LQTS) is characterized by a prolonged QT-interval in the 
electrocardiogram (ECG) and a propensity to develop polymorphous ventricular 
tachycardia (torsade de pointes arrhythmia) and ventricular fibrillation (Da Costa et al. 
2000; Hedley et al. 2009). Clinical symptoms include hypotensive syncopes and 
sudden death. While acquired LQTS may be related to electrolyte disturbances, 
structural heart disease or drugs (Chiladakis et al. 2012), congenital LQTS (cLQTS) is 
caused by mutations which, so far, have been detected in thirteen different genes 
coding for potassium-, sodium- or calcium channels or their interacting proteins 
(Hedley et al. 2009;Refsgaard et al. 2012). Interestingly, however, one study 
concluded that significant drug-induced prolongation of the terminal part of the QT 
interval (from the peak to the end of the T-wave) occurred only in first degree relatives 
of patients with drug-induced LQTS, not in relatives of individuals tolerating QT-
prolonging drugs. This indicates that drug-induced LQTS may also be influenced by 
genetic predisposition (Kannankeril et al. 2005).  
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The prevalence of cLQTS is uncertain, but has been estimated to be around 1:2000 in 
the general population (Schwartz et al. 2009). The genetic penetrance, however, may 
be low; in one study only 25 % of mutation carriers were symptomatic (Priori et al. 
1999). In the vast majority of affected cases the LQTS is considered to be the only 
characteristic, and a Romano-Ward syndrome, which has an autosomal dominant 
mode of inheritance, is present (Hedley et al. 2009). Much more rarely, the LQTS is 
associated with other organ manifestations. For example, patients with Jervell and 
Lange-Nielsen syndrome also have congenital deafness (Jervell & Lange-Nielsen 
1957); patients with Andersen syndrome may have other cardiac arrhythmias, 
malformations and periodic paralysis (Plaster et al. 2001; Tristani-Firouzi et al. 2002) 
and in some individuals also some cognitive impairment (Yoon et al. 2006), and in 
Timothy syndrome multiple organ manifestations, including cognitive deficit and 
autism, can occur (Splawski et al. 2004).  
Mutations in cardiac potassium- , sodium- or calcium channel genes may also cause a 
diversity of other rare inherited cardiac arrhythmias; (see Morita et al. 2008). These 
include the short QT syndrome, which is characterized by short QT intervals in the 
ECG and increased risk of atrial fibrillation and sudden death (Hedley et al. 2009), and 
the Brugada syndrome, which is also associated with an increased risk of sudden 
cardiac death and ECG showing ST-segment elevation in the right precordial leads and 
right bundle branch block (Vatta et al. 2002).  
1.5.3 Cardiocerebral channelopathies  
It has long been recognized that symptoms associated with cardiac arrhythmias in 
patients with the LQTS have been erroneously classified as epileptic seizures 
(Ballardie et al. 1983; Moss et al. 1991; O'Callaghan & Trump 1993), and a correct 
diagnosis of LQTS is frequently delayed because of misinterpretation of symptoms 
(MacCormick et al. 2009). Interestingly, however, many of the cardiac ion channel 
genes that have been associated with the LQTS are also expressed in the brain; (see 
Nashef et al. 2007), and there is emerging evidence that cardiac channelopathies can 
20 
 
cause not only cardiac arrhythmias and hypotensive syncopes, but possibly also 
genuine epilepsy. More than a decade ago, it was shown that the cardiac sodium 
channel gene, SCN5A, in which mutations cause LQTS type 3 (Refsgaard et al. 2012), 
is expressed in the limbic system of the rat brain (Hartmann et al. 1999), and a role in 
idiopathic seizure disorders was suggested. One year later the same gene was found to 
be expressed in the human brain (Donahue et al. 2000). More direct evidence from 
animal research was provided when it was shown that the potassium channel gene, 
KCNQ1, in which mutations are associated with the most common form of LQTS, 
LQTS type 1, is expressed in the forebrain and brainstem (Goldman et al. 2009). The 
authors also showed that animals with mutations in this gene had epileptic seizures 
with concomitant epileptiform activity in the electroencephalogram (EEG), and they 
also had malignant cardiac arrhythmias.  
Similarly, mutations in the gene encoding for the human ryanodine receptor (hRyR2) 
have been shown to cause catecholaminergic ventricular tachycardia, which is a 
potentially fatal cardiac arrhythmia (Priori et al. 2001). The ryanodine receptor is a 
calcium release channel (Imagawa et al. 1987) that is involved in the coupling between 
excitation and contraction (Kondo 1986; McPherson & Campbell 1993), and animal 
research has revealed that the cardiac isoform of this gene is also expressed widely in 
the brain (Otsu et al. 1990; McPherson & Campbell 1993).  Mice with a mutation in 
the RyR2 gene have been shown to display GTCSs in the presence of a normal heart 
rhythm and also exercise-induced ventricular tachycardias and sudden cardiac death 
(Lehnart et al. 2008). 
The clinical evidence indicating that cardiac channelopathies may cause epilepsy is 
limited. However, a mutation in the SCN5A gene and a rare variant in the cardiac 
potassium channel gene, KCNE2, in which mutations cause LQTS type 6 (Refsgaard et 
al. 2012), were detected in a patient with neonatal LQTS and epileptic seizures that 
occurred in the absence of a symptomatic cardiac arrhythmia. These results suggested 
the possibility that cardiocerebral channelopathies may explain both epilepsy and 
cardiac arrhythmias (Heron et al. 2010). This suggestion was in concordance with 
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another case report of a patient with a mutation in the potassium ion channel gene 
KCNH2 (hERG) (LQTS type 2) and a significantly prolonged QT interval in the ECG, 
syncopal events and torsade de pointes arrhythmia and also a history of tonic-clonic 
seizures and electroencephalographic abnormalities with paroxysmal slow waves 
provoked by photic stimulation (Omichi et al. 2010). Furthermore, the same mutations 
in the cardiac potassium channel genes KCNQ1 and KCNQ3 have been linked to both 
LQTS type 1 (Wang et al. 1996) and idiopathic epilepsy (Charlier et al. 1998).  
Studies of paroxysmal events in patients with LQTS have also revealed interesting 
similarities to epileptic seizures. In nine of 20 individuals with syncope and genetically 
proven LQTS, motor symptoms, including generalized tonic-clonic movements, were 
witnessed, and eight had urinary incontinence (MacCormick et al. 2011). The authors 
concluded that symptoms in relation to cardiac syncope might be more difficult to 
separate from non-cardiac causes than previously anticipated. However, they did not 
discuss the possibility that some of the seizure-like events may actually have been 
epileptic, e.g. in patients with generalized tonic-clonic movements and urinary 
incontinence. Another study on patients with LQTS concluded that a seizure 
phenotype was significantly more common in individuals with LQTS type 2, which is 
due to mutations in the cardiac KCNH2 gene, than in patients with other QT mutations 
(Johnson et al. 2009). This gene is also expressed in the hippocampus, and the authors 
discussed the possibility that these patients may have had epileptic seizures, although 
this was not proven as there was no electroencephalographic evidence of epilepsy.    
Similarly, in recent years, it has been discussed whether gene mutations that primarily 
have been associated with epilepsy, may also predispose epilepsy patients to cardiac 
arrhythmias. Two cases of sudden unexpected death in epilepsy (SUDEP) in a family 
with GEFS+ and mutations in the SCN1A gene were reported (Hindocha et al. 2008), 
and it was argued that the gene product of SCN1A, NaV1.1, is also present in the hearts 
of different mammals and may possibly have predisposed the patients to a fatal cardiac 
arrhythmia. Two years later a new SCN1A mutation was detected in another SUDEP 
victim with Dravet syndrome (Le Gal et al. 2010), and, again, it was discussed 
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whether an abnormal expression of this gene in the heart may possibly have been 
involved in the causation of SUDEP.  
 
1.6 Mortality in epilepsy 
At least since the middle of the Nineteenth Century, scientists have been concerned 
with the mortality caused by epileptic seizures. G. M. Bacon divided the epilepsy-
related causes of death into “1. Those arising from the long-continued effects of the 
disease on the body; 2. Deaths after a rapid succession of fits; 3. Sudden deaths in a 
fit; 4. Accidents due to fits” (Bacon 1868).  Later, over the years, a number of studies 
have confirmed that a proportion of people with epilepsy die prematurely because of 
seizures, but also the underlying diseases causing the epilepsy contribute to an 
increased mortality rate in the epilepsy population. 
1.6.1 Standardized mortality ratio 
The first published population-based study on mortality in the epilepsy population 
found that the overall mortality rate in individuals with epilepsy under the age of 50 
years was 3.5 times higher than expected, and in those over 50 it was 1.9 times higher 
than expected (Zielinski 1974). Some of the increased mortality documented in this 
study could be explained by brain lesions causing the epilepsy, including tumours and 
cerebrovascular disease. Since then, several population-based studies have confirmed 
that the mortality rate in epilepsy is significantly increased compared with the general 
population, commonly by estimating the standardized mortality ratio (SMR) which is 
the ratio between the observed number of deaths in a cohort over a defined period of 
time and the expected number of deaths, calculated according to the age and gender-
specific mortality rates in the reference population (Forsgren et al. 2005; Neligan et al. 
2011a). In population-based studies with many years of follow-up of incident cases of 
epilepsy, the SMR has been roughly between two and three (Cockerell et al. 1994; 
Lhatoo et al. 2001; Neligan et al. 2011a).  
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However, mortality rate varies with the period since seizure onset and is highest during 
the first year (figure 3) (Cockerell et al. 1994; Neligan et al. 2011a), mainly due to a 
higher proportion of patients with underlying life-threatening brain disorders in newly 
diagnosed epilepsy (Forsgren et al. 2005). Nevertheless, even many years after seizure 
onset, the mortality rate is significantly higher than in the general population (Neligan 
et al. 2011a). The reasons for this are not completely understood, but may, in part, be 
explained by underlying brain disorders causing the epilepsy and also seizure-related 
deaths. 
Figure 3 Standardized mortality ratios at different times of follow-up 
From Neligan et al. (Neligan et al. 2011a) 
The presence of underlying brain disorders in symptomatic epilepsy may also explain 
the higher mortality in this sub-group of epilepsy patients compared with those with 
idiopathic epilepsy (figure 3) (Lhatoo et al. 2001; Benn et al. 2009). Nevertheless, the 
mortality rate is also significantly increased in idiopathic epilepsy, with SMRs ranging 
from 1.6 to 1.8 (Hauser et al. 1980; Cockerell et al. 1994; Neligan et al. 2011a), 
although some studies report only a slight and statistically insignificant increment in 
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mortality, with SMRs ranging from 1.1 (Lindsten et al. 2000) to 1.3 (Olafsson et al. 
1998; Lhatoo et al. 2001). A possible explanation for the lack of statistically 
significant findings in the three last studies may be that patients with a single 
unprovoked seizure were included, and thus a proportion of these may not have 
developed epilepsy.  
In some selected sub-groups of epilepsy patients, the overall SMR has been found to 
be higher than in studies of population-based incident epilepsy. For example, a 
Swedish study on people with mental retardation (MR) (Forsgren et al. 1996) found 
significantly increased mortality rates with SMRs of 1.6, 5.0 and 5.8 in individuals 
with MR only, MR and epilepsy, and MR, cerebral palsy and epilepsy, respectively. 
Interestingly, mortality rate was highest in patients with only generalized onset 
seizures. In the patients with epilepsy and MR the mortality rate increased with seizure 
frequency during the year prior to the prevalence date, and only 6.7 % of the deaths 
were directly seizure-related. In a study of people with chronic epilepsy in a tertiary 
outpatient referral centre (Nashef et al. 1995b), the SMR was significantly increased at 
5.1, and as much as 58 % (14 of the 24 deceased) of the deaths were seizure-related. 
An even higher SMR of 15.9 (95 % confidence interval (CI) 10.6 – 23.0) was found in 
a residential school cohort of pupils with severe epilepsy and learning difficulty 
(Nashef et al. 1995a). Again, in this highly selected cohort, the majority of deaths 
(71.4 %; 20 of 28) were seizure-related. In another cohort of 245 patients with onset of 
epilepsy in childhood that was followed for 40 years (Sillanpaa & Shinnar 2010), the 
SMR of incident cases was significantly increased at 5.5, and 6.6 in the overall cohort. 
In this study too, the authors emphasized the influence of seizures on the mortality rate 
in the epilepsy population: mortality rate was elevated only in patients that were not 
seizure-free or had another neurological deficit, and the occurrence of seizures during 
the past five years was the most important risk factor for all causes of death. Similarly, 
the previously cited study from UK (Lhatoo et al. 2001), found that the mortality rate 
was increased in patients with generalized tonic-clonic seizures, and that patients with 
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congenital neurological impairment had a particularly high long-term SMR of 25 (95 
% CI 5.1 – 73.1).  
1.6.2 Proportionate mortality 
The UK study (Lhatoo et al. 2001) also reported the number of deaths associated with 
the leading of causes of death, and among the 195 deaths in individuals with definite 
epilepsy during the study period, 26 % died from neoplasms, 8 % from ischemic heart 
disease, and 12 % from cerebrovascular disease. Similarly, data from previous 
population-based studies (Zielinski 1974; Hauser et al. 1980; Annegers et al. 1984; 
Cockerell et al. 1994) have enabled calculation of proportionate mortality, which is the 
percentage of the total number of deceased within each category of causes of death 
(COD) (Forsgren et al. 2005). In these studies 12 – 14 % of the deaths were due to 
cerebrovascular disease, 8 – 19 % due to heart disease, 9 – 15 % due to brain tumours, 
and 20 – 35 % due to neoplasms (including brain tumours). Furthermore, 1.3 – 10 % 
of the deaths were seizure-related, and 0 – 4 % were classified as SUDEP. The 
diverging results between these studies may possibly be explained by differences in 
methods and duration (number of years) of follow-up.   
1.6.3 Cause-specific mortality 
The proportionate mortality ratio per se provides no information about the relative risk 
among people with epilepsy of dying from a specific cause, compared with the general 
population. However, several studies have estimated cause-specific mortality ratios 
where SMRs have been calculated for each specific category of COD. Significantly 
increased SMRs in the epilepsy population have been reported for neoplasms 
(excluding primary brain tumours), cerebrovascular disease and pneumonia ( Nilsson 
et al. 1997; Shackleton et al. 1999; Lhatoo et al. 2001; Neligan et al. 2011a), and, in 
some studies, also for heart disease (Annegers et al. 1984; Nilsson et al. 1997; Neligan 
et al. 2011a) and accidents (Hauser et al. 1980; Shackleton et al. 1999). From at least 
two cohort studies significantly increased SMR have also been reported for suicide 
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(Nilsson et al. 1997; Rafnsson et al. 2001). However, in one of these studies the 
increased risk was found only in men (Rafnsson et al. 2001), and in another cohort 
study the SMR for suicide was not significantly increased (Shackleton et al. 1999). 
Furthermore, in population-based studies suicide has been found to be very rare 
(Cockerell et al. 1994; Lindsten et al. 2000), and at present, to my knowledge, there is 
no convincing evidence from population-based studies of an increased occurrence of 
suicide associated with a diagnosis of epilepsy.  
As pointed out by Neligan et al. (Neligan et al. 2011a), at 20 to 25 years of follow-up 
the overall mortality rate in the epilepsy population was still significantly increased, 
and an important explanation for this appeared to be a higher occurrence of 
malignancy, ischemic heart disease, and pneumonia. However, as also underlined by 
the authors, a possible influence on mortality from comorbid conditions was not 
assessed. This may be of importance, since a number of potentially lethal conditions, 
including cardiovascular disease, chronic lung diseases, diabetes, pneumonia and 
neurodegenerative diseases, are more prevalent among people with epilepsy than in the 
general population (Gaitatzis et al. 2004). 
 
1.7 Sudden unexpected death in epilepsy (SUDEP) 
The directly seizure-related COD include sudden unexpected death in epilepsy 
(SUDEP), status epilepticus, drownings, and accidents. Of these, SUDEP is the most 
common (Nashef et al. 1995b; Sillanpaa & Shinnar 2010). During recent decades 
SUDEP has been a topic of considerable scientific interest, and, particularly over the 
last few years, an increasing number of review articles have focused on this tragic 
outcome of epilepsy that mainly affects young individuals (Tellez-Zenteno et al. 2005; 
Tomson et al. 2005; Tomson et al. 2008; Surges et al. 2009b; Nei & Hays 2010; 
Devinsky 2011; Neligan et al. 2011b; Shorvon & Tomson 2011; Hesdorffer & 
Tomson 2012; Surges & Sander 2012). 
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1.7.1 Definitions of SUDEP 
A review of 36 studies of incidence and risk factors revealed that SUDEP was clearly 
defined in 65 % of the studies, unclear in 29 %, and absent in 6 % (Tellez-Zenteno et 
al. 2005). However, it is claimed (Nashef et al. 2012) that in recent years the 
definitions proposed by Nashef (Nashef 1997) and Annegers (Annegers 1997) have 
been used in the majority of studies. Nashef (Nashef 1997) defined SUDEP as:  
‘‘Sudden, unexpected, witnessed or unwitnessed, nontraumatic and nondrowning 
death in patients with epilepsy, with or without evidence for a seizure and excluding 
documented status epilepticus, in which post mortem examination does not reveal a 
toxicologic or anatomic cause for death.’’  
whereas, according to Annegers, the criteria for SUDEP are: 
“1. The victim suffered from epilepsy, defined as recurrent unprovoked seizures. 
2. The victim died unexpectedly while in reasonable state of health. 
3. The death occurred “suddenly” (in minutes), when known. 
4. The death occurred during normal activities (e.g. in or around bed, at home, at 
work) and benign circumstances. 
5. An obvious medical cause of death was not found. 
6. The death was not the direct cause of the seizure or status epilepticus.“ 
Furthermore, “definite SUDEP” requires that autopsy was performed and all criteria 
were fulfilled, whereas in “probable SUDEP” post mortem is missing, but otherwise 
all criteria are met. In “possible SUDEP” an autopsy is lacking and the circumstances 
of the death are unclear, but SUDEP cannot be excluded. 
Recently a new definition of SUDEP was proposed (Nashef et al. 2012). This is a 
synthesis and clarification of the two previously described definitions from 1997. 
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However, since this new definition has not yet been used extensively in the literature, 
it will not be further reviewed here.  
1.7.2 Incidence 
In the epilepsy population, the rates of sudden death have been found to be up to 20 – 
40 times that of the general population. In a much-cited U.S. study, the estimated SMR 
of sudden death in the age group between 20 and 40 years was 23.7 (95 % confidence 
interval 7.7 – 55.0) (Ficker et al. 1998), whereas in another study, among patients 
between 14 and 21 years of age with epilepsy there were 188.6 cases of sudden death 
per 100.000  person-years at risk, compared with 4.6 per 100.000 in the general 
population (Neuspiel & Kuller 1985), and it has been stated that this very high relative 
risk of 40.2 cannot be disputed  (Annegers 1997). SUDEP is very rare in children; a 
study from Ontario, Canada, found an incidence of 2 per 10.000 person-years among 
children less than 18 years of age (Donner et al. 2001).  
However, the incidence of SUDEP varies widely, depending on the population being 
studied, duration of follow-up, and also on different methods used for case detection. It 
is lowest in population-based studies, particularly among newly diagnosed and 
seizure-free patients. In a prospective incidence cohort of patients with epilepsy, the 
incidence was 0.35 per 1000 person-years (Ficker et al. 1998), whereas another 
prospective population-based study with a shorter follow-up found an incidence of 
0.09 per 1000 patient-years (Lhatoo et al. 2001). In two other community-based 
studies of newly diagnosed epilepsy patients with a short follow-up (median 6.9 years) 
(Cockerell et al. 1994) or a low number of patient-years at risk (850) (Lindsten et al. 
2000), no cases of SUDEP were detected. Similarly, in two studies of epilepsy surgery 
patients no SUDEP occurred among seizure-free individuals (Sperling et al. 1999; 
Nilsson et al. 2003). In a prospective population-based study of a prevalence cohort of 
epilepsy patients, the incidence of SUDEP was 0.9 – 2.7 per 1000 patient-years 
(Leestma et al. 1989), whereas other community based studies have found an 
incidence from 0.3 to 1.5 per 1000 patient-years (Terrence et al. 1975; Langan et al. 
1998; Opeskin et al. 2000).    
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In different selected cohorts of epilepsy patients, the reported incidences have been 
higher. A study of SUDEP in the clinical development programme of the antiepileptic 
drug (AED) lamotrigine (LTG), which included patients with refractory epilepsy, 
revealed an incidence of SUDEP of 3.5 cases per 1000 patient-years (Leestma et al. 
1997), which is very similar to the incidence of 3.4 cases per 1000 patient-years 
reported from the cohort study of patients with severe epilepsy and learning difficulties 
(Nashef et al. 1995a), and also similar to the SUDEP incidence of 3.6 cases per 1000 
patient-years reported in a cohort of epilepsy patients with mental retardation (McKee 
& Bodfish 2000). Two studies from epilepsy clinics reported incidences of SUDEP of 
1.21 (Walczak et al. 2001) and 5 (Nashef et al. 1995b), respectively, whereas 
incidences of 6.3 (Nilsson et al. 2003) and 9.3 (Dasheiff 1991) per 1000 patient-years 
have been found among patients in epilepsy surgery programmes.  
Community-based studies have found that the proportion of deaths in the epilepsy 
population due to SUDEP ranges from 0 to 4 % (Zielinski 1974; Cockerell et al. 1994; 
Ficker et al. 1998; Lindsten et al. 2000; Lhatoo et al. 2001). In one of these studies, in 
which 1.7 % of the deaths were SUDEP, the corresponding percentage in the age 
group between 15 and 44 years was 8.6 (7 of 81) (Ficker et al. 1998). Of a cohort with 
onset of epilepsy in childhood, after 40 years of follow-up 7 % had died from SUDEP 
(Sillanpaa & Shinnar 2010). However, in the other more selected cohort studies, the 
proportions of deaths caused by SUDEP were considerably higher, ranging from 11.7 
% to 55 % (Nashef et al. 1995a; Nashef et al. 1995b; Sperling et al. 1999; Walczak et 
al. 2001; Nilsson et al. 2003; Hitiris et al. 2007). The highest proportion of SUDEP 
was found among patients with recurrent seizures after epilepsy surgery (Sperling et 
al. 1999). 
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1.7.3 Pathophysiological mechanisms 
Although no clear mechanism, common to all cases of SUDEP, has been identified 
there is considerable evidence that cardiac or respiratory mechanisms, or a 
combination of these, are involved. Most cases of SUDEP are unwitnessed (Nilsson et 
al. 1999; Langan et al. 2005; Lamberts et al. 2012). Nevertheless, evidence of a 
seizure in relation to the deaths has been reported in 22 % - 88 % of cases (Nashef et 
al. 1998; Kloster & Engelskjon 1999; Opeskin et al. 2000), and among documented 
observed cases, the majority occurred in relation to a GTCS (Terrence et al. 1975; 
Langan et al. 2000, 2005). Commonly, these deaths occur in bed or at home (Leestma 
et al. 1989; Nilsson et al. 1999; Langan et al. 2000; Hitiris et al. 2007), and a recent 
study of 154 SUDEP cases found that 58 % died during sleep (Lamberts et al. 2012).  
 
 
Respiratory dysfunction 
Airway obstruction may play a role in a proportion of SUDEP cases. In one 
retrospective case-control study, 17 of 24 cases (71 %) were found in the prone 
position (Kloster & Engelskjon 1999), whereas in another study evidence of possibly 
compromised airways was found in 42 % (11 of 26) of SUDEP cases (Nashef et al. 
1998). Central apnoea was documented in a case report of a near-SUDEP that occurred 
during video-electroencephalography (So et al. 2000). After a convulsive seizure the 
patient had prolonged apnoea, without evidence of airway obstruction or pulmonary 
oedema. During the first 10 seconds of the apnoeic period the ECG showed an 
unaffected heart rhythm, but thereafter it gradually slowed, before cardiac arrest after 
57 seconds. It is well-documented that central apnoea occurs in a significant 
proportion of epileptic seizures. In a study of individuals with refractory localization 
related epilepsy, 50 of 100 seizures were accompanied by central apnoea or 
hypopnoea, and 9 % by obstructive or mixed apnoea (Bateman et al. 2008). Pulse 
oxymetry showed significant reductions in oxygen saturation, in some individuals to 
below 70 %, and desaturation increased significantly with duration of the seizures. 
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Patients with oxygen saturation below 85 % also had retention of CO2. Similarly, 
another study of patients with complex partial and generalized seizures found that 
hypoxemia occurred in 25 % of seizures and correlated with seizure duration (Moseley 
et al. 2011). Furthermore, cases of neurogenic pulmonary oedema have been 
documented in relation to GTCSs and it has been suggested to be a contributory cause 
of SUDEP (Fredberg et al. 1988; Swallow et al. 2002; Pezzella et al. 2009). 
Pulmonary congestion and oedema are also common findings in autopsies of SUDEP 
cases (Terrence et al. 1981; Leestma et al. 1989).  
 
One documented SUDEP case occurred during ambulatory EEG showing epileptiform 
activity that was followed abruptly by flattening of the EEG (McLean & Wimalaratna 
2007). The authors reviewed two similar, previously published cases (Bird et al. 1997; 
Lee 1998) and suggested that electric cerebral shutdown was the “primary 
mechanism” of SUDEP, although neither respiration nor heart rhythm were monitored 
in this case report (McLean & Wimalaratna 2007). Nevertheless, the authors argued 
that the sudden flattening of the EEG was a “unique phenomenon” since in cardiac 
arrest or severe hypotension leading to global cerebral ischemia, flattening of the EEG 
is not sudden, but gradual. Shortly after this report, the significance of this seizure-
related sudden flattening of the EEG was explored in a case-control study in which 
results from video-electroencephalographic monitoring of individuals that had later 
died from SUDEP were compared with results from living controls (Lhatoo et al. 
2010). This study showed that postictal generalized electroencephalographic 
suppression (PGES) lasting for more than 50 seconds was significantly associated with 
SUDEP, and it was proposed that this cessation of electrical brain activity could be 
involved in the causation of SUDEP, possibly by inducing central apnoe. In 
contradiction to this, another study concluded that the risk of SUDEP was not related 
to the presence or duration of PGES, but PGES was associated with generalized 
seizures (Surges et al. 2011). Recently it was shown that PGES or postictal bilateral 
attenuation of the EEG was not associated with central apnoea, but with prolonged and 
severe oxygen desaturation and retention of CO2. The authors suggested that these 
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features were due to intrinsic pulmonary dysfunction (Seyal et al. 2012). Interestingly, 
evidence of underlying seizure-related autonomous dysregulation has recently been 
provided. In a study of 34 seizures in 11 patients, the degree of sympathetic activation 
and parasympathetic suppression correlated significantly with the duration of PGES 
(Poh et al. 2012). 
Importantly, seizure-induced respiratory and cardiac dysfunction may be related. In a 
clinical study, the likelihood of seizure-related abnormal prolongation or shortening of 
the QT interval in the ECG was shown to be significantly higher in the presence of 
hypoxemia than in its absence, with odds ratio 4.3 (95% CI 2.56 - 7.39) for 
prolongation of the QT interval and odds ratio 2.13 (95% CI 1.84 - 2.46) for QT 
interval shortening (Seyal et al. 2011).  
 
Animal research has also provided some evidence that respiratory mechanisms may be 
involved in SUDEP. In a sheep model in which status epilepticus was induced in the 
animals, severe central hypoventilation occurred in those that died, but not in surviving 
animals, and evidence of a fatal cardiac arrhythmia was not found (Johnston et al. 
1995). In a later study using the same animal model, all the sheep displayed central 
hypoventilation and apnoea, resulting in one death and considered to be contributory 
in another. One animal died from acute heart failure, but there were no cases of 
malignant cardiac arrhythmia (Johnston et al. 1997). However, death from status 
epilepticus is, per definition, not SUDEP (Annegers 1997; Nashef 1997), and although 
interesting, the implications of these findings for the understanding of the mechanisms 
underlying SUDEP are uncertain. 
 
Cardiac arrhythmia 
It has long been suspected that cardiac arrhythmias may underlie cases of SUDEP. 
Whereas inter-ictally the occurrence of arrhythmias has not been found to be 
significantly higher among people with epilepsy than in the general population 
(Blumhardt et al. 1986; Massetani et al. 1997), several reports have documented 
seizure-related arrhythmias, some of which have been potentially fatal.  
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Ictal sinus tachycardia is common and has been reported to occur in up to 99 % of 
seizures (Nei et al. 2000; Opherk et al. 2002; Nei et al. 2012), whereas sinus 
bradycardia is rare. A study of 20 patients with refractory localization-related epilepsy 
reported that sinus bradycardia (less than 40 beats per minute) occurred in eight of 377 
events (2.1 %) in seven patients  (Rugg-Gunn et al. 2004). This finding is very similar 
to that of a recent study of patients with treatment-resistant epilepsy in which four of 
217 (2 %) seizures in four of 75 patients (5 %) were accompanied by sinus bradycardia 
(Moseley et al. 2011). A variety of other abnormalities of heart rhythm and 
repolarization have been detected in relation to seizures. In a study of 43 patients with 
refractory epilepsy, 17 (39.5 %) had abnormalities of rhythm and/or repolarization in 
the ECG in relation to seizures (Nei et al. 2000). These included asystole, ventricular 
premature depolarizations, marked sinus arrhythmia, bundle-branch block, ventricular 
premature depolarizations and ST-segment elevations. Abnormalities were 
significantly more frequent in generalized seizures than in partial seizures, but there 
were no significant differences between pre-ictal and peri-ictal PR or corrected QT 
interval (QTc). Another study included 41 patients, in which 31 of 102 seizures were 
generalized (Opherk et al. 2002); ictal electrocardiographic abnormalities were found 
in 15 (37 %) of the patients, and in four patients (10 %) these were potentially serious, 
with prominent ST-segment depression or T-wave inversion. The electrocardiographic 
abnormalities were significantly more frequent in generalized seizures than non-
generalized seizures.  
A near SUDEP caused by ictal cardiac arrhythmia has been reported (Espinosa et al. 
2009). During video-electroencephalography the patient experienced a partial onset 
seizure that evolved into a GTCS, during which the patient had sinus tachycardia with 
180 beats per minute. At the end of the seizure the patient developed ventricular 
fibrillation that would have been lethal without cardiopulmonary resuscitation. A 
cardiac work-up, including heart catheterization and electrophysiologic study, did not 
reveal any abnormalities that could have predisposed the patient to a life-threatening 
arrhythmia. 
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In recent years, several studies have focused on the possible role of alterations in the 
QT interval in the causation of SUDEP. A study comparing results from video-
electroencephalography between 19 patients that later died from SUDEP with those 
from 19 matched controls concluded that neither peri-ictal prolongation of QTc nor 
other electrocardiographic abnormalities were significantly associated with SUDEP, as 
opposed to the frequency of GTCSs (Surges et al. 2010a). In another study, among 25 
epilepsy surgery patients 17 had abnormally shortened peri-ictal QTc and three had 
abnormally prolonged peri-ictal QTc (Surges et al. 2010b). QTc shortening, but not 
prolongation, was significantly associated with secondary generalized tonic-clonic 
seizures.  
However, other studies have found further evidence of seizure-related alterations in the 
QT interval, supporting a possible causative role in some cases of SUDEP. Of 156 
seizures that occurred during video-electroencephalography in 39 patients, 21 seizures 
in nine patients were associated with concomitant significant QTc prolongation 
(Brotherstone et al. 2010). Similarly, the already cited study that included 76 patients 
with a total of 218 seizures found clinically significantly prolonged QTc in 4.8 – 16.2 
% (depending on the method used when correcting the QT interval for heart rate) and 
QTc shortening in 3.8 – 4.8 % of seizures (Moseley et al. 2011).  
 
Abnormalities in the ST-segment and T-waves of the ECG have also gained interest as 
possible markers for increased risk of SUDEP. Among 19 patients with an implanted 
loop recorder, detecting a total of 1477 seizures, ictal repolarization abnormalities and 
cardiac arrhythmias were detected in eight individuals, including T-wave inversion or 
deepening, or ST-segment depression in four (Nei et al. 2012).  Again, it was 
concluded that these ictal cardiac abnormalities particularly occurred during 
generalized seizures.  
Increments of visible alternations from beat-to-beat of the amplitude or morphology of 
the ST-segment or T-wave (T-wave alternans) are independent predictors of 
cardiovascular mortality and sudden cardiac death (Rosenbaum et al. 1994; Nieminen 
& Verrier 2010; Strzelczyk et al. 2011). In a recent study of 16 patients with 
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treatment-resistant localization related epilepsy, secondary generalized tonic-clonic 
seizures preceded an increase in T-wave alternans for 15 minutes, and the authors 
discussed whether this parameter could possibly have a future role for estimating 
SUDEP risk in patients (Strzelczyk et al. 2011).  
 
In cardiac disease reduced heart rate variability (HRV) has been associated with 
increased risk of arrhythmias (see Ansakorpi et al. 2002). Reduced HRV has also been 
found in epilepsy patients, reflecting an altered autonomous influence on the heart 
rhythm (Tomson & Kenneback 1997). Among patients with temporal lobe epilepsy, 
reduction in HRV was most severe during the night (Ronkainen et al. 2005), and this 
may be of relevance since the majority of SUDEP cases occur during sleep (Lamberts 
et al. 2012). Interestingly, a case has recently been documented in which serial 
measurements showed increasingly abnormal HRV before SUDEP (Rauscher et al. 
2011). However, a small study including seven patients that later died from SUDEP 
and seven controls did not find any significant association between inter-ictal HRV 
and SUDEP (Surges et al. 2009a), and, at present, the role of HRV as a possible 
parameter in the risk stratification for SUDEP appears uncertain.  
 
Another parameter of potential interest in the evaluation of SUDEP risk is the 
ventricular late potentials (VLPs) that appear in the terminal part of the QRS complex 
in the signal-average electrocardiogram (SAECG) of patients with delayed activation 
of the myocardium. The presence of VLPs has been associated with an increased risk 
of ventricular tachycardia and fibrillation in patients with arrhythmogenic right 
ventricular cardiomyopathy (ARVC) (Santangeli et al. 2008) and in patients with low 
ejection fraction after acute myocardial infarction (Breithardt et al. 1991). ARVC is 
among the most common causes of sudden cardiac death in previously healthy young 
people (Sen-Chowdhry et al. 2010). Sudden death may be the first symptom (Sarvari 
et al. 2011), or the deceased may have had recurrent syncopes (Sen-Chowdhry et al. 
2010). Recently VLPs were detected in 22 of 45 (48 %) patients with chronic epilepsy, 
and, interestingly, the presence of VLPs correlated with well-known risk factors for 
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SUDEP: polytherapy, long duration of epilepsy, and frequent seizures (Rejdak et al. 
2011). However, this study was not sufficiently powered to enable evaluation of a 
possible influence of individual AEDs.    
 
1.7.4 Risk factors 
A diversity of risk factors for SUDEP have been reported from at least 48 studies 
(Hughes 2009), including studies of different selected epilepsy populations, 
uncontrolled case series, and studies using non-SUDEP deaths as controls. Different 
methods have been used in detecting the cases. However, results from studies using 
living controls with epilepsy are considered to be more reliable in reflecting the risk 
factors in the general epilepsy population (Tomson et al. 2008). There is wide 
agreement that the most important risk factor is high seizure frequency, and, in 
particular, frequent GTCSs (Tomson et al. 2008; Devinsky 2011; Duncan & Brodie 
2011; Shorvon & Tomson 2011; Surges & Sander 2012). Studies using living controls 
with epilepsy have focused on different risk factors, including different aspects of the 
influence of seizures. In two studies a high seizure frequency was identified as a risk 
factor (Nilsson et al. 1999; Walczak et al. 2001), whereas in another it was not 
(Timmings 1993). However, in the latter study SUDEP was significantly associated 
with idiopathic GTCSs. One study found that the occurrence of a seizure during the 
last year identified patients at a higher risk (Hitiris et al. 2007), whereas a high 
frequency of GTCSs was reported as a risk factor in another study (Surges et al. 
2010a) and a risk factor only in females in another (Walczak et al. 2001). In one study, 
a history of GTCSs during the last three months identified individuals at higher risk 
(Langan et al. 2005). Young age of onset was associated with a higher occurrence in 
two studies (Nilsson et al. 1999; Hitiris et al. 2007), whereas a long duration of 
epilepsy was a risk factor in two studies (Walczak et al. 2001; Hitiris et al. 2007), but 
not in another (Timmings 1993). Two studies found a higher occurrence of SUDEP 
among individuals with mental retardation (Jick et al., 1992;Walczak et al. 2001), 
whereas another study reported that supervision during the night was protective 
(Langan et al. 2005).  
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With respect to gender, two reports found that SUDEP was more common in males 
(Timmings 1993; Beran et al. 2004). Conversely, a large study including 154 SUDEP 
cases concluded that gender was not an independent risk factor (Langan et al. 2005), 
and, at present, there is no convincing evidence from population-based studies that the 
SUDEP risk in males differs from that in females.   
 
Several studies have found an increased risk among patients on polytherapy (Nilsson 
et al. 1999; McKee & Bodfish 2000; Nilsson et al. 2001; Beran et al. 2004), although 
this was not found in three other studies (Timmings 1993; Langan et al. 2005; Hitiris 
et al. 2007). The association of SUDEP with polytherapy has generally been 
interpreted as a reflection of poor seizure control (Tomson et al. 2008; Hesdorffer et 
al. 2012), although in one study polytherapy remained significantly associated with 
SUDEP after correction for seizure frequency (Walczak et al. 2001). Similarly, 
frequent changes of AED doses have also been connected with a higher risk of SUDEP 
(Nilsson et al. 1999; Nilsson et al. 2001).  
 
Some studies have focused on the possibility that patients that are not compliant with 
their antiepileptic medication may be at higher risk of SUDEP. One study in which 
AED concentrations were analysed in hair samples concluded that AED concentrations 
varied more over time in SUDEP victims than in controls, reflecting lower compliance 
(Williams et al. 2006). However, another report found that compliance of SUDEP 
victims at their last medical visit did not differ significantly from that of controls 
(Walczak et al. 2001). Results from investigations of psychotropic medication and 
SUDEP have also been conflicting: in one study the use of antipsychotics and 
axiolytics in females and males, respectively, was significantly associated with 
SUDEP (Nilsson et al. 1999), whereas in another study the use of psychotropic 
medication was not found to be a risk factor for SUDEP (Walczak et al. 2001). 
 
AEDs that have been shown to affect cardiac function may also have a possible 
influence on SUDEP risk in some patients. Carbamazepine (CBZ) and intravenous 
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phenytoin have been associated with cardiac conduction abnormalities with 
atrioventricular block, sinus bradycardia, and sinus arrest (Barron 1976; Kasarskis et 
al. 1992; Tomson & Kenneback 1997), and CBZ may also reduce heart rate variability 
(Tomson & Kenneback 1997; Persson et al. 2003; Lossius et al. 2007). Lacosamide 
may give rise to atrioventricular block (Ben-Menachem et al. 2007). Furthermore, 
retigabine can increase the QT interval in predisposed patients (Trobalt European 
Public Assessment Report, EPAR. Committee for Medicinal Products for Human Use 
(CHMP): www.ema.europa.eu/ema/), whereas the QT interval may be shortened in 
patients treated with primidone (DeSilvey & Moss 1980) or CBZ (Saetre et al. 2009). 
However, cardiac arrhythmias induced by AEDs have been found to occur mainly in 
predisposed patients (Kenneback et al. 1991; Saetre et al. 2009; Sevcencu & Struijk 
2010), and among the AEDs mentioned above, only treatment with CBZ (Timmings 
1998; Langan et al. 2005) or high serum concentrations of this drug (Nilsson et al. 
2001) have been connected with an increased risk of SUDEP. However, two other 
studies concluded that patients on CBZ were not at a higher SUDEP risk (Walczak et 
al. 2001; Hitiris et al. 2007), and recently the ILAE, Commission on Epidemiology, 
Subcommission on Mortality concluded their combined analysis of previous research 
data on SUDEP with a statement that no single AED increases the risk of SUDEP 
(Hesdorffer et al. 2012). 
 
In 2005 a cell experimental study documented that LTG inhibits the cardiac potassium 
current IKr (Danielsson et al. 2005). Previous reports had shown that drugs with a 
similar potential to inhibit the IKr are associated with prolonged QT interval in the 
ECG, torsade de pointes arrhythmia, syncope and sudden cardiac death in patients 
(Witchel & Hancox 2000; Redfern et al. 2003). The authors suggested that their 
finding could be of clinical importance under certain conditions, such as high serum 
concentrations, concurrent treatment with other IKr blocking drugs or seizure-induced 
acidosis. At that time, however, no clinical studies had suggested an increased risk of 
SUDEP in patients being treated with LTG.  
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Aims of the study 
 
Background 
During the 10-year period between August 1 1995 and July 31 2005, four consecutive 
cases of definite SUDEP were registered among non-hospitalized patients at 
Neurological Department, Stavanger University Hospital, Stavanger, Norway. All four 
cases were females with idiopathic epilepsy that had been treated with LTG in 
monotherapy. These cases did not emerge through systematic study, but were 
registered as they appeared in the clinical setting. The study described in this thesis 
was initiated because of the striking similarities between the deceased. 
 
Objectives 
 
Our objectives were to: 
1. Evaluate whether our clinical observation could be due an increased risk of SUDEP 
in sub-groups of epilepsy patients being treated with LTG.  
2. Explore the potential underlying causes of the previously described significantly 
increased mortality among people with epilepsy, even many years after seizure onset. 
 
In order to meet these objectives we: 
x Described and discussed the four cases in the light of relevant literature    
(paper I). 
x  Performed a post mortem analysis of the long QT syndrome genes of the four 
deceased patients (paper II). 
x Estimated the incidence of SUDEP in our county and investigated whether the 
use of LTG was associated with an increased risk of SUDEP in females or other 
epilepsy patient sub-groups (paper III). 
40 
 
x Evaluated the feasibility of using signal-averaged electrocardiography in 
combination with standard electrocardiography to detect cardiac abnormalities 
in newly diagnosed epilepsy patients without clinical evidence of heart disease 
and investigated whether the initiation of therapy with the commonly used 
antiepileptic drugs LTG or CBZ gave rise to VLPs or significant abnormalities 
in the standard ECG (paper IV). 
x Investigated the distribution of the different COD in an epilepsy population and 
compared this with the general population in the same catchment area and also 
with reports from other epilepsy populations. In addition, to evaluate the 
contribution of comorbid diseases to the mortality, we studied the chronological 
relationship between the onset of epilepsy and the diseases leading to death 
(paper V).  
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Materials and methods 
Paper I describes the review of hospital records and post mortem reports of the four 
SUDEP victims and also provides a review of the literature to evaluate the likelihood 
of a relationship between the use of LTG and SUDEP in sub-groups of epilepsy 
patients.  
Stavanger University Hospital serves a population of about 300.000 in the southern 
part of Rogaland County. Data obtained from Farmastat AS (http://www.farmastat.no) 
showed that LTG during the 10-year period in Rogaland County had a mean market 
share in defined daily doses (DDD) of 6.7 %, and consequently the accumulation of 
registered SUDEP cases on LTG did not appear likely to be due to a high proportion of 
epilepsy patients being treated with the drug.  
 
In paper II a post mortem genetic analysis in the four deceased is described, based on 
our hypothesis that a genetic predisposition to cardiac arrhythmia may have played a 
role in causing their deaths. The method previously described by Berge et al. (Berge et 
al. 2008) was used for DNA sequencing of the translated exons with flanking intron 
sequences of the LQTS-associated genes KCNQ1, hERG, SCN5A, minK and MiRP1. 
 
Paper III describes a systematic study of SUDEP in Rogaland County, Norway 
during the 10-year period. SUDEP cases were identified by review of autopsy reports 
and data from the Norwegian Cause of Death Registry, which includes all cases in 
which epilepsy was listed as a direct or contributory causes of death (N = 136). In 
addition, from the Norwegian Cause of Death Registry we obtained the direct and 
contributing COD of all patients that had been registered at Stavanger University 
Hospital with a diagnosis of epilepsy and had died during the same period (N = 268). 
Only patients with a permanent address in Rogaland County were included in the 
analysis. In all cases in which SUDEP was considered to be a possible cause of death, 
the hospital records were reviewed. Inclusion of cases was based on the Nashef criteria 
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for SUDEP (Nashef 1997) and cases were classified as definite, probable or possible 
as previously described (Annegers 1997; Tomson et al. 2008). In order to estimate the 
number of epilepsy patients at risk we multiplied the number of residents each year in 
the County (Statistics Norway: http://www.ssb.no) by 0.7 %, which is the estimated 
prevalence of epilepsy in western countries (Hauser et al. 1991; Sander 2003; French 
& Pedley 2008). To estimate the number of patient-years at risk for each AED, the 
market share in Rogaland of each antiepileptic drug, in DDD, was obtained from 
Farmastat AS (http://www.farmastat.no).   
 
At least three living controls for each SUDEP case were randomly selected from 
among patients that had been registered with a diagnosis of epilepsy at Stavanger 
University Hospital during the same year that the SUDEP had occurred. In order to 
investigate whether age or gender could be risk factors for SUDEP, a primary 
unmatched control group of 89 and 120 individuals was selected for definite and 
probable, and for definite, probable and possible SUDEP, respectively. A further 
secondary control group, with three to four controls matched by age and gender for 
each SUDEP victim, was selected for the remaining analyses that included possible 
risk factors for SUDEP; 63 controls were used for definite and probable SUDEP and 
86 controls for definite, probable and possible SUDEP. Since the market share of the 
different AEDs changed during the period of interest, the clinical data from the 
medical records of the controls were extracted from the year in which the 
corresponding SUDEP occurred. Classification of epilepsy syndromes in cases and 
controls was based on the ILAE 1989 definition (ILAE, 1989). Detailed information 
on market shares of AEDs and the clinical data that were analysed are available in 
paper III, tables 1 and 2, respectively. 
 
Paper IV describes a prospective study of 26 individuals (19 females and seven 
males) with newly diagnosed epilepsy that had not previously been treated with an 
AED. All patients went through a somatic and neurological examination and also 
cerebral magnetic resonance imaging (MRI) and standard electroencephalography. 
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The patients were diagnosed with epilepsy according to the ILAE and the International 
Bureau for Epilepsy 2005 definition (Fisher et al. 2005), and their epilepsy syndromes 
were classified according to the ILAE 1989 definitions (ILAE, 1989). A prerequisite 
for inclusion in the study was the absence of clinical evidence of cardiac disease. At 
inclusion (T0) and three to nine months after initiation of therapy with LTG or CBZ 
(T1), a routine 12-lead electrocardiography and signal-averaged electrocardiography 
were conducted, and routine blood tests, including haematologic analyses, electrolytes, 
creatinine and erythrocyte sedimentation rate were performed. The choice of AED was 
made according to the clinical judgement of the attending physicians. The signal-
averaged electrocardiography was performed as previously described (Sarvari et al. 
2011). When at least two of the following three criteria were fulfilled, a VLP was 
considered to be present: 1) Total filtered QRS duration (fQRSd) of > 114 ms; 2) 
terminal (last 40 ms) QRS root-mean-square voltage (RMS) of < 20 μV; and 3) low 
amplitude (< 40 μV) late potential duration (HFLA) of  > 38 ms. 
 
In paper V the hospital records and COD among the 268 deceased epilepsy patients 
from Stavanger University Hospital during the 10-year period were reviewed. Four 
patients were excluded because of lack of evidence in the medical records that the 
patients had been diagnosed with epilepsy. Two additional cases of SUDEP were 
included; these had died during the 10-year period, but had been registered with a 
diagnosis of epilepsy only prior to the study period. Thus, a total of 266 deceased were 
included. 
The distributions of age and gender among living epilepsy patients at the end of the 
study period (N = 2480) were obtained from the database of Stavanger University 
Hospital, and the corresponding information about the general population of Rogaland 
County per January 1 2005 (N = 393,104) obtained from Statistics Norway 
(www.ssb.no). From Statistics Norway, we also obtained the number of deaths within 
each defined category of age, gender and COD in the county during the study period. 
The diagnostic categories included ‘‘cerebrovascular’’ (ICD - 9 430 – 438; ICD - 10 I 
60 – 69), ‘‘heart disease’’ (ICD - 9 393 – 398, 410 – 414, 415.0 and 420 – 429; ICD -
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10 I05 – I09, I 20 – I25, I27 and I30 – I52), ‘‘neoplasm (excluding brain tumours)’’ 
(ICD - 9 140 – 190, 192.2 – 224 and 225.3 – 239; ICD - 10 C00–C69, C70.1, C72.0, 
C72.1, C73 – C97, D32.1, D33.4, D34 – D48), ‘‘brain tumours’’ (ICD - 9 191, 192.0, 
192.1, 225.0 – 2; ICD - 10 C71, C72.2 – C72.8, C70.0, D32.0, D33.0 –  D33.3), 
‘‘pneumonia’’ (ICD - 9 480 – 486; ICD - 10 J12–J18), ‘‘suicide’’ (ICD - 9 E950 – 
E959; ICD - 10 X6n), ‘‘accidents’’ (ICD - 9 E800 – E929; ICD - 10 V0n–V99, W0n – 
X59, X8n, Y85 – Y89) and ‘‘other’’. 
 
3.1 Statistical analyses 
Papers I and II are case reports and did not include statistical analyses.                    
Paper III: Before conducting the study, a power analysis was performed to evaluate 
whether data from a population of about 400,000 over a 10-year period could be 
sufficient for detecting an increased risk of SUDEP in patients that were treated with 
LTG, compared with epilepsy patients not on this drug. Given a prevalence of epilepsy 
of 0.7 %, an incidence of SUDEP of 1.4 per 1000 patient-years at risk (Nilsson et al., 
1999) and a mean market share in DDD of 6.7 %, an anticipated relative risk of three 
could be detected with a power of 80 % at significance level of 0.05.  
Due to the statistical uncertainty connected with small numbers, statistical analysis 
was only performed when there were at least five observations. For comparisons of 
frequencies between cases and matched controls, conditional odds ratios for matched 
age and sex case–control design were estimated using Epi Info version 3.5.1 (Center 
for Disease Control, Atlanta, GA, U.S.A.).  
The web-based software Open Epi (http://www.openepi.com) was used to estimate 
rate ratios with 95 % confidence intervals of SUDEP incidence among patients on a 
particular AED compared with the incidence among those not on this drug.  
Mean duration of epilepsy was compared between cases and matched controls using a 
linear mixed model with a random intercept in SPSS (version 18; IBM Corporation, 
Armonk, NY, U.S.A.). Analyses were also performed in SPSS when cases were 
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compared with unmatched controls: Pearson’s chi-square tests were used for 
frequencies and Mann-Whitney tests for means. Because the primary outcome of the 
case-control study was the proportion of cases on LTG compared with the proportion 
of controls on this drug, correction for multiple comparisons was not performed. 
 
Paper IV: The parameters in the ECG and SAECG at T0 and T1 were compared using 
Student's paired samples t-test in SPSS/PASW.  
 
Paper V: Comparisons of proportionate mortality ratios between deceased epilepsy 
patients and deceased from the general population were performed in SPSS using 
Pearson’s chi-square and Fisher Exact tests. 
   
3.2 Ethical approval 
The studies were approved by the Regional Committees of Medical Research Ethics, 
as described in the articles. Informed consent was obtained from controls (paper III) 
and patients (paper IV). 
 
3.3 Methodological considerations 
The case reports in papers I and II are the first published clinical observation 
suggesting the possibility of an increased risk of SUDEP in sub-groups of patients 
being treated with LTG, and the first cardiac channelopathy detected in a SUDEP 
victim. Clearly, our observations could not permit any definite conclusions to be 
drawn regarding whether or not there is an increased risk of SUDEP connected with 
the use of LTG or, if present, whether this is due to a possible arrhythmogenic effect of 
the drug or an insufficient efficacy of the drug in controlling seizures. Nevertheless, in 
the light of the available literature our findings gave reason to initiate a systematic 
study to try to address these questions. 
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In SUDEP victims the reason(s) for the final seizure being lethal, often after several 
years of living with treatment-resistant epilepsy, remain largely unknown. Since 
SUDEP is a rare event, a prospective study of incident cases of epilepsy, in which a 
sufficient number of patients on different AEDs are followed for many years, would be 
practically impossible to conduct. In searching for risk factors, the aim is to identify 
factors that differentiate those that died from those that have survived (Hesdorffer & 
Tomson 2012). Therefore, in order to investigate whether the use of LTG is connected 
with an increased risk of SUDEP, we used living epilepsy patients as controls (paper 
III) in our nested case-control study.  
In addition we used the market share, in DDD, of AEDs to estimate relative risks of 
SUDEP in individuals being treated with a particular AED compared with those that 
were not on that drug. In order to obtain a correct reflection of the proportion of 
individuals on a specific drug, a prerequisite would be a small difference between the 
DDD, as defined by the World Health Organization, and the mean dose in the study 
population. Concerning LTG, the DDD is 300 mg 
(http://www.whocc.no/atc_ddd_index/), which was considerably higher than the mean 
LTG dose among our cases and controls (197 mg and 158 mg, respectively); a fact of 
which we became aware during the process of analysis of our data. However, we 
performed a conservative correction of the estimated number of patient-years at risk on 
LTG, based on the number of individuals on LTG in 2005, as recorded at 
www.reseptregisteret.no, and also the assumption that the proportion of females 
among LTG users did not increase, but was stable at the 2005 level during the course 
of the 10-year period.     
In order to avoid a hypothesis-driven finding of a drug-related SUDEP risk that would 
not be replicated in future studies because of lack of scientific consistency, we used a 
conservative approach in inclusion of cases. For example, one female on LTG was 
found dead in a bath tub, and, because there was no evidence of submersion, could 
have been classified as a possible SUDEP, according to the recently published 
proposed definition of SUDEP (Nashef et al. 2012). However, we considered 
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drowning to be the most likely cause of death, and the case was therefore classified as 
a non-SUDEP. Similarly, another female patient on LTG was found dead with 
abundant gastric content on the pillow and was therefore classified as a possible 
SUDEP. However, aspiration of gastric content could also have been considered to be 
a terminal event, rather than a possible cause of death, and consequently this case 
could have been classified as a probable SUDEP.   
 
Although our study in Rogaland County documented a statistically significantly 
increased risk of SUDEP in females on LTG, we were aware that our conclusion was 
based on a limited number of cases. We therefore acknowledged in the published 
article that our findings must be confirmed in future studies before definite conclusions 
are reached.  
   
In the study described in paper IV, signal-averaged electrocardiography was 
performed in combination with standard electrocardiography. To the best of our 
knowledge among people with epilepsy, this procedure has only been performed in a 
population with chronic epilepsy (Rejdak et al. 2011). Although only a small number 
of patients were included, the study provided important information supporting the 
notion that cardiac arrhythmias induced by AEDs occur primarily in predisposed 
individuals. As no female with idiopathic epilepsy was treated with LTG, it was not 
possible to investigate whether the drug may give rise to cardiac side effects in this 
sub-group of epilepsy patients.       
 
The study design described in paper V did not permit estimation of cause-specific 
mortality, which could have provided information on the relative risks among people 
with epilepsy of dying from a specific cause of death compared with the general 
population. However, a major strength of this study was the review of the medical 
records of the deceased, adding new insights into the explanations underlying the 
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significantly increased mortality rate that has previously been documented in the 
epilepsy population.  
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Results 
Paper I 
The four deceased females were 16 – 37 years of age. They had all been treated with 
LTG in monotherapy, and diagnosis after post mortem examination was definite 
SUDEP. In all cases, the medical history and results from neurological examination, 
electroencephalography and cerebral MRI were consistent with idiopathic epilepsy.  
Paper II 
Case one was heterozygous for a novel missense mutation, R523C in exon 12 of the 
SCN5A gene (GenBank Accession number: NM_198056.2, which corresponds to 
XP_001131636 in the published article (paper II)) coding for the cardiac sodium 
channel, voltage gated, type V, alpha subunit. The mutation changes codon 523 from 
arginine to cysteine, and was predicted by the prediction program PolyPhen to be 
pathogenic.  
Ictal semiology in this patient had included a feeling of déjà vu, indicating  
localization-related epilepsy, whereas the electroencephalography showed bilateral 
synchronous epileptiform activity, which is more consistent with generalized epilepsy. 
Unfortunately, cardiac disease was not suspected ante mortem and therefore 
electrocardiography was not conducted. 
For the other three cases, genetic analysis did not reveal any abnormalities. 
Paper III 
We identified 16 definite, three probable and seven possible cases of SUDEP: 15 were 
female and 11 male. Of these 26 cases, 10 (38.5 %) had been treated with LTG, and 
nine of these patients were female. Seven of 12 females with definite and probable 
SUDEP (58.3 %) and 10 of 41 controls matched for age and gender (24.4 %) were on 
LTG (p = 0.038, 95 % CI 1.1 – 28.2).  
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In females, the incidence of definite and probable SUDEP was estimated as 2.5 per 
1000 patient-years among those that were treated with LTG and 0.5 per 1000 patient-
years in those that were not treated with LTG (p = 0.007, incidence rate ratio 5.0, 95 % 
CI 1.6–17.3). Mean dose and duration of treatment on LTG did not differ significantly 
between cases and controls.  
The incidence of SUDEP in Rogaland County during the 10-year period was 0.7 per 
1000 patient-years for definite and probable SUDEP, and 1.0 per 1000 patient-years 
when all cases were included. 
Concerning other AEDs no significant differences in incidences of SUDEP between 
cases that were taking/not taking a particular drug were detected, and, similarly, there 
was no significant difference between the proportion of cases and controls that were 
on a particular drug.  
The proportions of cases and controls with IGE were similar (about 25 %) and also 
among female SUDEP victims on LTG, the difference between cases and controls was 
not statistically significant. However, when including the patient with a known SCN5A 
mutation (case one) and also case 11, in which the epilepsy syndrome had primarily 
been considered unclassifiable, the proportion with idiopathic epilepsy among female 
SUDEP victims on LTG was significantly higher than in controls.                                                        
Neither the distribution of age and gender, nor the proportion with duration of epilepsy 
for more than 10-years, or onset before 16 years of age differed significantly between 
cases and controls. However, the proportion of patients between 20 and 40 years of 
age was significantly higher among cases (13 of 19; 68 %) than controls (30 of 89; 34 
%) (p = 0.005). Mean duration of epilepsy did not differ significantly between cases 
(16.25 years) and controls (15.15 years), or, in particular, between cases on LTG 
(13.25 years) and controls (13.59 years).  
 
Paper IV 
In one of the 26 patients, a VLP was present at baseline, whereas the standard ECG 
was normal. Cardiac MRI showed a reduced thickness of the free part of the right 
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ventricular wall and possibly some fatty infiltration. This patient was therefore 
excluded from the remaining part of the study. Twenty-five patients (18 females and 7 
males) completed the study; 15 were treated with LTG and 10 with CBZ. At baseline, 
the total number of GTCSs did not exceed two in any patient. For the 25 patients, both 
the standard ECG and SAECG were within normal limits at T0 and T1, and no 
significant abnormalities in the blood parameters were detected. The AED 
concentrations at T1 were sub-therapeutic in five patients on LTG and in two patients 
on CBZ, but otherwise they were within range. 
 
Paper V 
The distributions of the COD among the 266 epilepsy patients and the 29,332 deceased 
in the general population are shown in table 2 (paper V). Deaths from brain tumours 
were excluded from the comparisons between the deceased epilepsy patients and the 
deceased from the general population. A significantly lower proportion of epilepsy 
patients died from cardiac disease (39 of 220; 17.7 %) than in the general population 
(8095 of 29114; 27.8 %) (p < 0.001; 95 % CI 0.389 – 0.801). Otherwise there were no 
significant differences of proportionate mortality between the epilepsy patients and the 
general population. Onset of cardiac disease or cerebrovascular disease had preceded 
seizure onset in at least 71.8 % of the patients that died from cardiac disease, and 
among those that died from cerebrovascular disease the epilepsy was secondary to 
cerebrovascular disease in 72 %. Similarly, among patients that died from neoplasms, 
the malignancy had preceded seizure onset in at least 43 %. Furthermore, all the eight 
deceased from pneumonia had severe underlying and/or comorbid predisposing 
conditions, and both of the two suicide victims had experienced significant 
psychosocial distress before onset of epilepsy. 4.5 % of the epilepsy patients died from 
definite and probable SUDEP, and 6.8 % – 10.2 % of the deaths were seizure-related.  
The distribution of age and gender were fairly similar in the epilepsy population at risk 
compared with the general population (table 3).  
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Discussion  
It is well recognized that the mortality rate in people with epilepsy is significantly 
higher than in the general population, and that underlying diseases and, in some 
degree, direct seizure-related deaths, contribute to this increase (Cockerell et al. 1994; 
Shackleton et al. 1999; Lhatoo et al. 2001; Forsgren et al. 2005; Neligan et al. 2011a). 
However, the extent to which this increase in mortality rate is due to the disorder itself 
or to unrelated conditions that are not caused by epilepsy, is unclear.  
SUDEP is the most common of the direct seizure-related causes of death in epilepsy 
patients, and the majority of victims are young adults. The possibility that the choice 
of AED treatment may play a role for the SUDEP risk has been discussed for many 
years. However, a common interpretation of available research data has been that no 
particular AED appears to be associated with an increased SUDEP risk (Walczak 
2003; Tomson et al. 2005; Surges et al. 2009b; Hesdorffer et al. 2012).  
 
5.1 Is treatment with lamotrigine associated with an increased risk of 
SUDEP in sub-groups of epilepsy patients?  
 
Paper I was the first clinical report suggesting the possibility of an increased risk of 
SUDEP in sub-groups of epilepsy patients being treated with LTG. Although we 
acknowledged that one of the possible explanations for our observation could be that 
LTG was not sufficiently efficacious in controlling seizures, our main hypothesis was 
that an arrhythmogenic effect of the drug in genetically predisposed individuals may 
have played a role. This was largely based on the finding of an IKr blocking effect of 
the drug in an experimental cell-based study (Danielsson et al. 2005), despite there 
being no unequivocal relationship between the demonstration of an IKr blocking effect 
in the laboratory and an arrhythmogenic effect in patients (Webster et al. 2002; 
Redfern et al. 2003). Shortly after our report (paper I) was published, a study of 152 
healthy individuals concluded that there was no evidence that LTG increases the QT 
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interval in the ECG (Dixon et al. 2008). These authors also argued that the incidence 
of SUDEP in the clinical development programme of LTG was 3.5 per 1000 patient-
years, which was considered to be no higher than expected (Leestma et al. 1997). 
Nevertheless, whether it is scientifically acceptable to extrapolate from 
electrocardiographic findings in healthy volunteers to patients with epilepsy or, in 
particular, patients with idiopathic epilepsy, is open to discussion. Similarly, the 
clinical development programme only included patients with localization related 
epilepsy, and therefore the conclusions from this study may not be valid in idiopathic 
epilepsy.   
Although, as we also acknowledged, the finding that all the four cases had idiopathic 
epilepsy could have been coincidental, another possibility could be that patients with 
idiopathic epilepsy may be genetically predisposed to drug-induced cardiac 
arrhythmia, and that patients with this predisposition may be at increased risk when 
exposed to an IKr blocking drug. The suggestion that the same channelopathy may 
cause both the long QT syndrome and epilepsy (Hartmann et al. 1999) provided an 
important basis for this hypothesis and, as described in the introduction, in recent years 
there has been increasing evidence for the existence of cardiocerebral channelopathies 
and overlapping phenotypes between cardiac and cerebral channelopathies. However, 
the extent of this overlap is presently unknown, and in idiopathic epilepsy it is not 
known whether a genetic predisposition for cardiac arrhythmia is present in only a 
minor proportion of cases or is more common.      
The novel SCN5A mutation that was detected in one of the four deceased (paper II) 
was the first documentation of a cardiac channelopathy in a SUDEP victim. The ictal 
semiology of this patient had included episodes of déjà vu, which originates in the 
limbic system (Wild 2005). Since this gene is also expressed in the limbic system of 
the rat brain (Hartmann et al. 1999), this mutation may possibly have been an 
underlying cause of both the epilepsy and a susceptibility to cardiac arrhythmia. 
Interestingly, one study that included analysis of long QT syndrome genes in 48 
deceased that were considered to have died from SUDEP revealed a mutation in 6 
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(12.5 %), and the findings were claimed to provide “proof-of-principle to conduct a 
more comprehensive prospective study of SUDEP cases” (Tu et al. 2011). However, in 
this cases series, for the majority of patients neither classification of seizures and 
epilepsy syndromes, nor results from electroencephalography were reported, and thus 
there is a lack of certainty regarding whether these patients had genuine epilepsy. In 
our patient with an SCN5A mutation, because cardiac disease was not suspected ante 
mortem a cardiac work-up was not conducted, and therefore it could be argued that the 
mutation may not have been disease-causing. Additionally, as many non-pathogenic 
mutations have been detected in the region of R523C in the SCN5A gene, it has been 
suggested that the mutation detected in our patient was not likely to be disease-causing 
(Johnson et al. 2010). Importantly, however, it should be mentioned that this particular 
mutation causes an amino acid substitution - from arginine to cysteine. This implies an 
alteration in charge, and, based on the analysis by the prediction program PolyPhen, it 
appears that this mutation is likely to be pathogenic.  
 
Patients with QT mutations may be particularly susceptible to lethal arrhythmia when 
treated with IKr blocking drugs (Schwartz 2006). Therefore, if the assumption is 
correct that the mutation in our patient was pathogenic, treatment with LTG could 
have provided greater potential for inducing cardiac arrhythmia than treatment with 
this drug in a patient without a cardiac channelopathy.   
 
Paper III describes a population-based study that sought to reveal whether treatment 
with LTG is associated with an increased risk of SUDEP in sub-groups of epilepsy 
patients, and also to estimate the incidence of SUDEP in Rogaland County. Whereas 
the incidence of SUDEP in the general epilepsy population was similar to that which 
has been documented in previous population-based studies, we found a significantly 
higher incidence of SUDEP in females that were treated with LTG than in females that 
were not on this drug. Additionally, a significantly higher proportion of female 
SUDEP victims were on LTG than matched controls. There was no evidence for an 
increased risk of SUDEP among males. One possible explanation for this 
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preponderance of females among SUDEP victims on LTG could be that the drug 
possesses an IKr blocking ability, since the risk of drug-induced torsade de pointes 
arrhythmia is higher in females than in males (Makkar et al. 1993; Lehmann et al. 
1999; Viskin et al. 2003).  
In a recent combined analysis of data from previous case-control studies of SUDEP, in 
the crude analysis the risk of SUDEP was significantly higher in patients with IGE that 
had been treated with LTG compared with controls (odds ratio 2.20; 95 % CI 1.14 - 
4.23), whereas the risk was not increased in those without IGE that were treated with 
LTG (Hesdorffer et al. 2011). The authors stated that their finding was in line with our 
own report (paper I), in which we suggested an increased risk with treatment with 
LTG in idiopathic epilepsy. Interestingly, they also found that the risk of SUDEP in 
patients on LTG was significantly increased when onset of epilepsy was under the age 
of 16 years, whereas it was not increased in those with a later seizure onset. Whether 
this could be explained by the fact that onset of idiopathic epilepsy usually occurs in 
childhood and adolescence (Benbadis 2005), thereby resulting in a higher proportion 
of patients with idiopathic epilepsy among patients with early onset, was not 
discussed. We found about the same proportion (about 25 %) of IGE in cases and 
controls, and also among female SUDEP victims on LTG the difference was not 
statistically significant. However, as described in the introduction, idiopathic epilepsy 
encompasses not only IGE, and when including case one with a known SCN5A 
mutation and also case 11, which primarily had been considered to be unclassifiable, 
the proportion of those with idiopathic epilepsy among female SUDEP victims on 
LTG was significantly higher than in controls. 
We found no evidence of an increased risk of SUDEP connected with any other AED. 
Taken together, we found a significantly increased risk of SUDEP in female patients 
on LTG and also some support for the notion that this finding of an increased risk may 
possibly be explained by an increased SUDEP incidence with LTG only in idiopathic 
epilepsy, although our findings did not permit any firm conclusions.     
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5.2 Is there a causal relationship between the use of lamotrigine and a 
higher occurrence of SUDEP in female patients?  
 
Only months after the identification of LTG use as a potential risk factor for SUDEP 
in IGE (Hesdorffer et al. 2011), the same authors stated that they had provided a 
consistent message that it is the number of GTCSs that increases SUDEP risk, and not 
AEDs (Hesdorffer et al. 2012). This conclusion was reached after a new analysis 
showed that when the frequency of primary or secondary generalized tonic-clonic 
seizures had been controlled for then LTG was not associated with a significantly 
increased risk of SUDEP. Interestingly, however, and in concordance with our own 
findings, a similar gender difference was detected, although it was not statistically 
significant, with an odds ratio for SUDEP in females on LTG of 6.6 compared with 0.4 
in males. The lack of statistical significance after controlling for the frequency of 
GTCSs implies that a causal relationship could not be detected in a mixed epilepsy 
population with primary and secondary generalized tonic-clonic seizures. However, 
IGE was not analysed separately, and, given the possibility that the risk is only 
increased in IGE and not in localization related epilepsy, the definite conclusion that 
there is a lack of association between LTG use and SUDEP may have been reached 
too hastily.  
Recently the occurrence of SUDEP was examined in 42 randomized controlled LTG 
trials sponsored by GlaxoSmithKline (Tomson et al. 2012). Among patients on LTG, 
were two male and two female definite and probable SUDEP. In the placebo-
controlled studies, the odds ratio for SUDEP in patients on LTG was 0.22 (95 % CI 
0.00–3.14), whereas it was 2.18 (95 % CI 0.17 – 117) when an active comparator had 
been used. Although no evidence was found for a significantly increased risk of 
SUDEP connected with LTG treatment, the authors emphasized the wide confidence 
intervals, indicating that “a clinically important effect cannot be excluded”. Although 
the vast majority of patients included in their analysis had localization related epilepsy, 
there was also a small proportion with primary generalized seizures, and there were no 
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SUDEP cases among these patients. However, as stated by the authors, the duration of 
follow-up was limited. Furthermore, as only 647 patients with primary generalized 
seizures were included in the analysis, the number of patient-years at risk was too low 
to enable evaluation of risk in this sub-group of patients. Nevertheless, this study 
provides some evidence that SUDEP risk in patients with localization related epilepsy 
on LTG therapy is not significantly increased. This conclusion is in concordance with 
the findings from the clinical development programme of LTG, in which only patients 
with localization related epilepsy were included (Leestma et al. 1997), and is also 
consistent with our findings in which the majority of female SUDEP victims on LTG 
had idiopathic epilepsy. Interestingly, however, the finding of an odds ratio of 0.22 
when LTG treatment was compared with placebo, although not statistically significant, 
could give some support in the direction of a protective effect against SUDEP of LTG 
in localization related epilepsy, compared with no treatment. This is also in line with 
the conclusion from a recent meta-analysis of randomized trials, including a number of 
different AEDs, in which add-on treatment with AEDs in efficacious doses was 
associated with a significantly lower SUDEP risk compared with placebo (Ryvlin et 
al. 2011).      
 
In our study we could not correct for the frequency of GTCSs because information on 
the frequency of the different seizure types was lacking in several of the hospital 
records, and this has been used as a basis for arguing against a causal relationship 
between use of LTG and SUDEP (Pack 2012). Although logistic regression analysis, 
including seizure frequency totalling more than one per week, identified LTG as an 
independent risk factor, we have not excluded the possibility that our findings may be 
due to a higher frequency of GTCSs and have no association with a pro-arrhythmic 
effect of the drug.  
 
One possible explanation for an increased occurrence of SUDEP in patients with 
idiopathic epilepsy that have been treated with LTG may be that there is a weaker 
protective effect against GTCSs with LTG in comparison with other AED treatments. 
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In a prospective unblinded randomized study (the SANAD study), LTG was 
significantly less efficacious than valproate in treatment of IGE (Marson et al. 2007), 
although this study did not specify whether this also applied to GTCSs in particular. 
Similarly, in a study on newly diagnosed epilepsy patients, 39 % of those with juvenile 
myoclonic epilepsy achieved seizure control with LTG treatment compared with 75 % 
using valproate (p = 0.014) (Mohanraj & Brodie 2005). To the best of my knowledge, 
no published study on patients with IGE has documented that treatment with LTG is of 
an equal or higher efficacy than treatment with any other AED.  
Another possible explanation for an increased occurrence of SUDEP in patients on 
LTG could be that despite the lack of efficacy that may be associated with this AED, 
patients continue to take LTG because it is well tolerated and a lack of effect on 
seizure control may not have been definitively demonstrated.   
 
It has also recently been suggested that our findings may be explained by low (or 
absent) serum concentrations of LTG (Hesdorffer & Tomson 2012), although the 
possibilities of a drug reaction or an arrhythmogenic effect in genetically predisposed 
patients were also acknowledged. In support of this explanation, are the findings of 
low or absent serum concentrations of LTG at post mortem examination in four of the 
seven deceased females that had been treated with LTG. Surprisingly, the argument 
that post mortem serum concentrations are unreliable (Tomson et al. 1998) was not 
mentioned in the discussion that proposed this explanation. Nevertheless, the 
possibility of low serum concentrations and consequently an insufficient protective 
effect against seizures at the time of SUDEP cannot be excluded. In addition, as also 
inferred (Hesdorffer & Tomson 2012), the serum concentrations of LTG at the time of 
SUDEP may also have been low in two other cases. However, it seems unlikely that 
low serum concentrations, resulting in a higher propensity for GTCSs, represent the 
whole explanation, as this does not address the issue, both from our own data and also 
information from the combined analysis (Hesdorffer et al. 2011),  regarding the 
increased risk of SUDEP apparently only being associated with idiopathic epilepsy.  
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Furthermore, if a low serum concentration of AEDs is a major explanatory factor in 
SUDEP in general, then a higher occurrence of SUDEP is less likely to be associated 
with a particular AED, but with any AED in which clinically relevant serum 
concentrations are not maintained. It also seems unlikely that female patients on LTG 
are treated differently to those on other AEDs. Generally, a change in antiepileptic 
medication is considered when seizure control is unsatisfactory. In a female patient 
with poor seizure control and a low serum concentration of LTG, the dose would 
commonly have been increased, regardless of whether the low serum concentration 
was caused by, for example, co-medication with an oral contraceptive (which has been 
shown to cause a reduction in serum concentrations of LTG by more than 50 % 
(Sabers et al. 2003)).      
 
A common denominator of the two drugs, CBZ and LTG, which have both been 
suggested to be associated with an increased risk of SUDEP, is that there is evidence 
that they may affect cardiac function. At present, however, there is insufficient 
knowledge regarding whether a drug effect on cardiac rhythmicity may be involved in 
the causation of SUDEP. Paper IV describes a study that sought to reveal whether 
LTG or CBZ affect cardiac function in newly diagnosed epilepsy patients without 
clinical evidence of cardiac disease. Furthermore, this study also evaluated the 
feasibility of using signal-averaged electrocardiography in combination with standard 
electrocardiography to detect cardiac abnormalities in this patient group. One patient 
with a VLP at baseline was excluded from the rest of the study, otherwise no 
electrocardiographic abnormalities were detected at baseline nor after three to nine 
months on treatment with LTG or CBZ. This lack of findings in patients without 
evidence of cardiac abnormalities supports the view that cardiac arrhythmias or 
conduction abnormalities caused by AEDs primarily occur in predisposed individuals. 
The results are also in line with a previous study on cardiac effects of the same drugs 
in elderly patients, in which no significant electrocardiographic abnormalities were 
detected after initiation of AED therapy (Saetre et al. 2009). In that study patients with 
significant atrioventricular conduction defect were excluded from participation.  
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The reason in SUDEP for the final seizure being lethal, after several years with 
treatment-resistant epilepsy, is poorly understood. Since SUDEP is very rare in newly 
diagnosed epilepsy patients (Cockerell et al. 1994), whereas a long duration of 
epilepsy has been identified as a risk factor for SUDEP (Walczak et al. 2001; Hitiris et 
al. 2007), it is important to try to understand the underlying mechanisms that might 
explain why patients with long-standing epilepsy may be at a higher risk. Our finding 
of a VLP at baseline in only one of twenty-six patients with newly diagnosed epilepsy 
may therefore be an important observation when compared with the 48 % of patients 
with chronic epilepsy in which a VLP was detected (Rejdak et al. 2011). The patients 
with a VLP had a significantly longer duration of epilepsy and also a significantly 
higher seizure frequency compared with those without a VLP. A possible explanation 
could be that the extensive autonomous activation that occurs during GTCSs may 
cause fibrosis or vacuolization of the myocardium, which, in turn, may be a substrate 
for a malignant cardiac arrhythmia (Earnest et al. 1992; Natelson et al. 1998). In our 
study no patient had experienced more than two GTCSs, and this may explain why 
electrocardiographic abnormalities were not detected in any of the twenty-five patients 
that completed the study. Another possible explanation for the absence of VLPs 
among our patients may be that they were all on monotherapy, whilst in the patients 
with a VLP the number of AEDs per patient was significantly higher than in those 
without a VLP (Rejdak et al. 2011). However, whether the VLPs were related to a 
drug effect or to an anatomic substrate in the myocardium for a potentially malignant 
arrhythmia could not be determined from that study.       
 
From our findings it appears that electrocardiographic abnormalities induced by LTG 
or CBZ in the inter-ictal phase are not common in newly diagnosed epilepsy patients 
without clinical evidence of cardiac abnormalities. However, since in our study only 
one male patient with IGE was treated with LTG and no female patients, our study did 
not provide information on the potential effect on the ECG from this drug in these sub-
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groups of patients. Furthermore, since the electrocardiographic recordings were 
conducted inter-ictally, a potential drug effect in the ictal phase has not been excluded. 
The detection of a VLP in the SAECG in one patient, and the subsequent finding of 
significant right ventricular pathology, demonstrates that the method may be a useful 
supplement to standard electrocardiography to detect significant cardiac abnormalities 
in patients with newly diagnosed epilepsy. However, a general recommendation of 
using signal-averaged electrocardiography in these patients should not be made on the 
basis of a single finding.         
 
5.3 What are the most important explanations for the increased mortality in 
the general epilepsy population? 
 
The most important finding in our study on mortality in the epilepsy population 
(paper V) was that many of the deaths were due to conditions with onset prior to the 
onset of epilepsy. For more than 70 % of patients that died from cardiac or 
cerebrovascular disease, the onset of these diseases preceded the onset of epilepsy, and 
in at least 43 % of the deaths from neoplasms, the onset of malignancy occurred prior 
to seizure onset. Similarly, all eight deaths from pneumonia occurred in patients with 
severe underlying or comorbid conditions, and both patients that died from suicide had 
experienced significant psychosocial distress before seizure onset. That for a high 
proportion of cases, the ultimately fatal disorders emerged prior to the onset of 
epilepsy shows that the chronological relationship between onset of epilepsy and onset 
of the disorders leading to death is highly relevant, and must be taken into 
consideration when evaluating whether the epilepsy precipitates an elevated risk of 
dying from a particular specified cause.     
 
When a clinician is faced with a patient with newly diagnosed epilepsy, the question 
about the risk of premature death may arise. As described in the introduction, several 
studies have reported a significantly increased mortality rate and cause-specific 
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mortalities for different causes of death in the epilepsy population compared with a 
reference population. However, one common denominator of these studies has been 
that the presence of underlying or comorbid disorders, except brain tumours, has not 
been accounted for at inclusion into these investigations (Hauser et al. 1980; Nilsson et 
al. 1997; Shackleton et al. 1999; Lhatoo et al. 2001; Neligan et al. 2011a). In order to 
evaluate whether the diagnosis of epilepsy, or its treatment, implies an increased risk 
of dying from a particular disorder, it is crucial that individuals that already suffer 
from that disorder at seizure onset are excluded from the analysis. Since this 
apparently has not been done, the reported increase in standardized mortality ratio for, 
for example, cancer, may not imply that the risk of dying from a malignant neoplasm 
is increased in a patient with newly diagnosed epilepsy and without a known 
malignant disorder than for any other appropriately matched individual.   
 
In our study, there were no significant differences in proportionate mortality compared 
with the general population, except from a significantly lower proportion of deaths 
from cardiac disease. Additionally, the distributions of age and gender in the 
populations at risk were fairly similar in the two populations. Importantly, however, 
these results do not permit a conclusion to be reached concerning the relative risk in 
the epilepsy population of dying from a particular cause, since our study design did not 
allow calculation of SMRs. Several studies have addressed the possibility of a 
relationship between epilepsy and cardiac disease, but the results have been 
conflicting. A recent study (Chuang et al. 2012) found that treatment with old-
generation AEDs was associated with unfavourable alterations in blood lipids and 
other vascular risk factors, whereas an earlier study on males between 30 and 50 years 
of age with chronic epilepsy revealed no differences in risk factors for coronary heart 
disease compared with controls (Nakken & Kornstad 1998). Some studies have also 
found significantly increased standardized mortality ratios in epilepsy for cardiac 
disease (Annegers et al. 1984; Nilsson et al. 1997; Neligan et al. 2011a), although in 
one of these studies statistical significance was not detected before a follow-up of up 
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to 25 years (Neligan et al. 2011a). Furthermore, in another  of these studies a 
significantly higher mortality from heart disease was found only in individuals less 
than 65 years of age (Annegers et al. 1984). Conversely, in our study, only three of the 
39 deaths from cardiac disease occurred in individuals under 65 years of age. Given 
that the majority of those that died from cardiac disease in our study had already 
developed vascular disease at onset of epilepsy, none of these data provide convincing 
evidence that the diagnosis of epilepsy per se implies an increased risk of dying from 
cardiac disease. Nevertheless, an increased risk in sub-groups of epilepsy patients may 
still be possible, e.g. in individuals on long-term therapy with old-generation AEDs.  
The proportionate mortality ratios in our epilepsy population were largely similar to 
those that have been reported from previous studies. However, there were differences 
for some causes of death, particularly when compared with more selected cohorts from 
the UK (White et al. 1979; Klenerman et al. 1993), in which the proportion of deaths 
due to brain tumours was similar to that in our general population (0.7 %). The 
proportions with SUDEP (4.5 %) and seizure-related deaths (6.8 % - 10.2 %) were 
also similar to findings from population-based studies (Zielinski 1974; Hauser et al. 
1980; Annegers et al. 1984). However, in one population-based study (Cockerell et al. 
1994), there were no cases of SUDEP and only 1.3 % of deaths were seizure-related, 
probably because of a short follow-up time in a population with newly diagnosed 
epilepsy.   
 
5.4 Strengths and limitations of the study 
 
Our study provided the first clinical report in which the possibility of an increased risk 
of SUDEP in epilepsy patients being treated with LTG is discussed. Also, to my 
knowledge, our study provided the first report suggesting a possible risk connected 
with treatment with a specific AED may be may depend on gender and epilepsy 
syndrome. The finding of an SCN5A mutation in one of four SUDEP victims also 
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provided the first evidence of a cardiocerebral channelopathy in a SUDEP victim, 
indicating the possibility that a genetic predisposition to cardiac arrhythmia might play 
a role in the causation of SUDEP. However, as a cardiac work-up was not performed 
in this patient, there was no clinical evidence that the mutation predisposed the patient 
to cardiac arrhythmia. 
In our population-based study, cases of SUDEP were identified by three different 
methods, and therefore it is unlikely that many cases were missed. In order to ensure 
reproducible reliability in our results, a conservative approach was used for inclusion 
of cases. Another strength of our study was that the risk of SUDEP was evaluated both 
by a nested case-control design, with living epilepsy patients as controls, and by 
estimation of incidence rate ratios for each AED.  
 
However, the study also had some limitations of which the most important were the 
relatively low number of observations, and the inability to correct for the frequency of 
GTCSs. Because of the latter limitation, we were unable to exclude the possibility that 
the increased occurrence of SUDEP in females on LTG could be due to a higher 
frequency of GTCSs, rather than as a direct result of an adverse effect of the drug in 
genetically predisposed individuals. 
Further information on the strengths and limitations of the study is described under 
“Methods” – methodological considerations. 
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Conclusions 
One aim of this thesis was to evaluate whether our clinical observation regarding four 
consecutive cases of SUDEP in a clinical environment could reflect an increased risk 
of SUDEP in sub-groups of epilepsy patients being treated with LTG. In addition, the 
thesis explored the underlying causes of the previously described significantly 
increased mortality rate among people with epilepsy, even many years after seizure 
onset. 
Among female SUDEP victims, the proportion treated with LTG was significantly 
higher than in matched controls. Furthermore, whereas the incidence of SUDEP in 
Rogaland County was similar to that which has been reported from previous 
population-based studies, the incidence in females on LTG treatment was significantly 
higher than in females not being treated with this drug.  
We found no evidence of an increased risk of SUDEP in male patients treated with 
LTG or an increased risk of SUDEP connected with any other AED.  
Although our findings provided some evidence that an increased risk of SUDEP 
associated with treatment with LTG occurs only in idiopathic epilepsy patients, no 
firm conclusions could be reached due to the unavoidable limitations of our study. 
Nevertheless, in line with our reports, recent studies have confirmed an increased 
occurrence of SUDEP in patients with IGE that have been treated with LTG and a 
preponderance of females among SUDEP victims being treated with this drug. 
As we were unable to correct for the frequency of GTCSs in our study, it was 
impossible to ascertain whether the increased occurrence of SUDEP in females being 
treated with LTG is due to a causal effect, possibly through an arrhythmogenic effect 
in genetically predisposed individuals, or to insufficient efficacy of LTG at seizure 
control.  
We found no electrocardiographic abnormalities inter-ictally after initiation of 
treatment with LTG or CBZ in newly diagnosed epilepsy patients without evidence of 
cardiac abnormalities, suggesting that cardiac abnormalities caused by these drugs are 
not common in similar cohorts. However, the study did not permit firm conclusions to 
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be reached about the possible arrhythmogenic potential of these drugs, since the 
recordings were only conducted in the inter-ictal phase, and there were no female 
patients with IGE and being treated with LTG in our study cohort. 
  
Of the deaths in the epilepsy population, 4.5 % were caused by definite and probable 
SUDEP, and 6.8 %, or maximally 10.2 %, were seizure-related. Otherwise, the 
majority of deaths were due to underlying or comorbid conditions, among which the 
onset of these conditions preceded the onset of epilepsy in a significant proportion of 
cases. Apart from the contribution from the directly seizure-related deaths, the 
significantly increased mortality rate previously described in the epilepsy population 
may be explained, at least in part, by underlying diseases and comorbid conditions that 
are not caused by epilepsy.  
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Future perspectives 
Although our study revealed a significant association between treatment with 
lamotrigine in females and SUDEP, one limitation was that this potentially very 
important finding was based on relatively few observations. Therefore our results 
should be confirmed in a larger study before a firm conclusion is reached. 
Nevertheless, since an increased occurrence of SUDEP in sub-groups of patients on 
LTG has been confirmed, at least partly, in other studies, one important future issue 
may be to explore the underlying reasons for these findings. In particular, there is a 
need to explore the degree of overlap between cardiac and cerebral channelopathies, as 
knowledge of a genetic predisposition towards cardiac arrhythmia in individual 
patients may be of vital importance. Sudden cardiac death in these patients may be 
preventable by appropriate treatment, e.g. with a β-blocker or implantation of a 
cardioverter-defibrillator (Garratt et al. 2010), and it may be important to avoid IKr 
blocking drugs in these patients because of their particular vulnerability to drug-
induced, potentially fatal cardiac arrhythmia (Schwartz 2006). 
Furthermore, whether individual AEDs influence cardiac rhythmicity during the ictal 
phase, and whether or not gender and epilepsy syndrome is of importance, need to be 
explored.  
Finally, to support the interpretation of blood concentrations of specific AEDs from 
future post mortem examinations of SUDEP cases, animal research could provide 
valuable information on the fate of the blood concentrations of various AEDs, 
including LTG, after death. Studies on genetically modified animals with cardiac 
channelopathies could also provide valuable information on the potential effects of 
individual AEDs on cardiac function during and between seizures. 
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